Výsledky vyhledávání - "Rupert H. Davies"

Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer

Autor: Jeffrey R, Proctor, Elaina M, Gartner, Todd E, Gray, Rupert H, Davies

Publikováno v: Cancer chemotherapy and pharmacology. 90(5)

To characterize the pharmacokinetics (PK) of zanidatamab including evaluation of the impact of intrinsic and extrinsic patient factors. To investigate alternative dosing regimens to improve caregiver convenience and reduce zanidatamab wastage.Serum z

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5c6482753c553f236f590b4e986d2b80
https://pubmed.ncbi.nlm.nih.gov/36102999

Zobrazit plný text záznamu

Abstract 2935: ZW270, a conditionally masked IL-12 cytokine fusion protein displaying potent anti-tumor activity absent systemic toxicity

Autor: Maya C. Poffenberger, Jennifer L. Bishop, Ryan J. Blackler, Kevin G. Haworth, Steven Booth, Shalla Hanson, Jeff R. Proctor, I-Ting Shao, Nichole K. Escalante, Dayananda Siddappa, Joel Smith, Gursev Anmole, Saki Konomura, Nicholas A. Dawson, Sifa Arrafi, Desmond Lau, Gerry Rowse, Rupert H. Davies, Thomas Spreter von Kreudenstein

Publikováno v: Cancer Research. 83:2935-2935

IL-12 is a pleiotropic cytokine that potently stimulates anti-tumor cytotoxic T and NK cell mediated immunity. Recombinant IL-12 reduces tumor growth in multiple mouse models, but its therapeutic application has been limited by severe toxicities. Pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4ce2847d4ba0b7753f41e7b03785e454
https://doi.org/10.1158/1538-7445.am2023-2935

Zobrazit plný text záznamu

Abstract 3914: ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers

Autor: Fung Vincent K C, Jamie R. Rich, Rupert H. Davies, Phil W. Hammond, Stuart D. Barnscher, Geoffrey C. Winters, Adam S. Galey, Andrea Hernandez, John Babcook, Grant Raymond Wickman, Kevin J. Hamblett, Tong Ding

Publikováno v: Cancer Research. 78:3914-3914

Therapies targeting HER2 have transformed the treatment of patients with HER2-expressing breast and gastric cancers. Unfortunately, many patients recur following HER2-targeted treatments and new therapies are needed. Multiple antibody-drug conjugate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b939e7ec854125db4324a74db605224
https://doi.org/10.1158/1538-7445.am2018-3914

Zobrazit plný text záznamu

Abstract 3912: Towards development of next-generation biparatopic ADCs using a novel linker-toxin with expanded therapeutic window

Autor: John Babcook, Patrick G. Kaminker, Fung Vincent K C, Stuart D. Barnscher, Grant Raymond Wickman, Laurence Madera, Peter Wing Yiu Chan, Rupert H. Davies, Marylou Vallejo, Kevin Yin, Kevin J. Hamblett, Jamie R. Rich

Publikováno v: Cancer Research. 78:3912-3912

Antibody drug conjugate (ADC) therapies such as Kadcyla® and Adcetris® have significantly improved outcomes for patients. Despite these early advances, many ADCs have failed due to tolerability and efficacy concerns; therefore, there is a need to d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cdd6007946e1f344c536e789600f12d4
https://doi.org/10.1158/1538-7445.am2018-3912

Zobrazit plný text záznamu

Abstract 31: Preclinical development of a novel biparatopic HER2 antibody with activity in low to high HER2 expressing cancers

Autor: Gerry Rowse, Rupert H. Davies, Grant Raymond Wickman, Nina E. Weisser

Publikováno v: Cancer Research. 77:31-31

HER2-directed therapies have improved clinical outcomes for many patients with HER2 overexpressing breast and gastric cancer. Despite these successes, there remains a need to develop effective HER2-targeted therapies for these and other HER2-expressi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5b96b52509afbaf27257d7c8677f54ae
https://doi.org/10.1158/1538-7445.am2017-31

Zobrazit plný text záznamu

ZW38, a Novel Azymetric Bispecific CD19-Directed CD3 T Cell Engager Antibody Drug Conjugate with Controlled T Cell Activation and Improved B Cell Cytotoxicity

Autor: Grant Wickman, Rupert H. Davies, Thomas Spreter, Gordon Yiu Kon Ng

Publikováno v: Blood. 128:1841-1841

Although blinatumomab is an approved treatment for Philadelphia chromosome negative relapsed or refractory (r/r) precursor-B cell ALL and is under development for r/r B cell NHL, blinatumomab has several limitations impacting fuller therapeutic utili

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f60331e66f5043f3e3c0cb0628df1922
https://doi.org/10.1182/blood.v128.22.1841.1841

Zobrazit plný text záznamu

Optical enhanced luminescent measurements and sequential reagent mixing on a centrifugal microfluidic device for multi-analyte point-of-care applications

Autor: Joseph D. Andrade, Daniel A. Bartholomeusz, Rupert H. Davies

Publikováno v: Advanced Biomedical and Clinical Diagnostic Systems IV.

A centrifugal-based microfluidic device 1 was built with lyophilized bioluminescent reagents for measuring multiple metabolites from a sample of less than 15 μ L. Microfluidic channels, reaction wells, and valves were cut in adhesive vinyl film usin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::703414609634d5c96664246afcf5c62c
https://doi.org/10.1117/12.669226

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání